Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor

British Journal of Haematology

Volumn 118, Issue 1, 2002, Pages 181-188

  Kasahara, Senji ^a   Hara, Takeshi ^a   Itoh, Hiroyasu ^a   Ando, Kazuki ^a   Tsurumi, Hisashi ^a   Sawada, Michio ^a   Yamada, Toshiki ^a   Ohnishi, Hiroo ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

Author keywords

Blood; Cellular differentiation; Human; Stem cells; TNFR

Indexed keywords

CD34 ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

APLASTIC ANEMIA; ARTICLE; BONE MARROW DISEASE; CANCER RISK; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOLOGY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION;

ACUTE DISEASE; ADULT; AGED; ANEMIA, APLASTIC; ANTIGENS, CD; ANTIGENS, CD34; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STEM CELLS;

EID: 0036066904     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03592.x     Document Type: Article

References (55)

1. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis
2. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL
3. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA working party
4. Myelodys-plastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?
5. Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression
6. World Health Organization classification of the acute leukemias and myelodysplastic syndrome
7. Proposals for the classification of the myelodysplastic syndromes
8. Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons
9. Tumor necrosis factor-alpha increases hepatic DNA and RNA and hepatocyte mitosis
10. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome
11. Hepatitis-associated aplastic anemia
12. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-gamma
13. + cells
14. + hematopoietic progenitor cells
15. Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon
16. Liver regeneration
17. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine
18. Hypoplastic myelodysplasia (MDS)
19. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice
20. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways
21. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
22. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
23. Further evidence for lymphokine overproduction in severe aplastic anemia
24. Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions
25. Production of hematopoietic regulatory cytokines by peripheral blood mononuclear cells in patients with aplastic anemia
26. Incidence of aplastic anemia: The relevance of diagnostic criteria
27. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes
28. Cytotoxic and stimulatory effects of antilymphocyte globulin (ALG) on hematopoiesis
29. Induction of differentiation in embryonic stem cell by 26-kD membrane-bound tumor necrosis factor (TNF) and 17-kD free TNF
30. Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndrome and aplastic anemia
31. Morphology and classification of the myelodysplastic syndromes and their pathologic variants
32. + progenitors for autologous and allogeneic transplantation in children
33. Fas antigen expression on human marrow cells is induced by interferon-γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro
34. + cells of patients with aplastic anaemia
35. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes
36. Hypoplastic myeloblastic syndrome: Incidence, morphology, cytogenetics, and prognosis
37. Liver regeneration
38. T cell-mediated inhibition of erythropoiesis in aplastic anaemia: The possible role of IFN-γ and TNF-α
39. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells
40. Interferon-γ gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia
41. Hypoplastic myelodysplastic syndrome
42. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor
43. + selection systems
44. Comparable TNF-alpha, IFN-gamma and GM-CSF production by purified normal marrow CD3 cells in response to horse anti-lymphocyte and rabbit anti-thymocyte globulin
45. Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia
46. Detection of tumor necrosis factor-α in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia
47. Interferon-γ constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition
48. Increased production of tumor necrosis factor-α by peripheral blood mononuclear cells in patients with aplastic anemia
49. Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma
50. Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: In vitro evidence for the presence of immunosuppressive mechanism
51. - progenitor cells
52. Hypocellular myelodysplastic syndromes (MDS): New proposals
53. Sequential promotion of normal and leukemic hemopoiesis by recombinant human granulocyte colony-stimulating factor during the myelodysplastic syndrome
54. Tumor necrosis factor primes hepatocytes for DNA replication in the rat
55. Aplastic anemia and non-A, non-B hepatitis